Logo

Hayden Jeffreys, Joanne Mason

Nov 03, 2017

Cambridge Epigenetix has appointed Hayden Jeffreys as chief operating officer and Joanne Mason as vice president of biomarker discovery. Jeffreys has previously served as interim CEO of Erba Diagnostics, as well as head of corporate business development and strategy for Erba Mannheim and Lumora. He has also held senior positions at Lab21 and Gen-Probe (now part of Hologic).

Mason was previously director of sequencing and sample acquisition for Genomics England, where she managed sample collection and sequencing for the 100,000 Genomes Project. She also set up and managed an NGS core facility at Oxford University Hospitals NHS Foundation Trust. She holds a PhD from the University of Cambridge and sits on the MHRA Genomics for Diagnosis Forum, UK NEQAS for molecular genetics DNA extraction steering committee, and Genomics England sequencing advisory board.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.